2348 — Dawnrays Pharmaceutical (Holdings) Income Statement
0.000.00%
Last trade - 00:00
- HK$1.80bn
- HK$780.75m
- CNY1.15bn
- 85
- 92
- 74
- 98
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 950 | 1,024 | 1,165 | 1,278 | 1,151 |
Cost of Revenue | |||||
Gross Profit | 536 | 551 | 675 | 767 | 642 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 619 | 669 | 679 | 777 | 695 |
Operating Profit | 331 | 355 | 486 | 501 | 456 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 314 | 331 | 439 | 438 | 414 |
Provision for Income Taxes | |||||
Net Income After Taxes | 255 | 265 | 354 | 356 | 323 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 255 | 268 | 358 | 358 | 326 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 255 | 268 | 358 | 358 | 326 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.166 | 0.175 | 0.201 | 0.217 | 0.145 |
Dividends per Share | |||||
Special Dividends per Share |